At the AUA 2024 Annual Meeting, Eric Li, MD, of Northwestern University, highlighted his recent analysis on the significance of adverse pathologic features at radical prostatectomy for active surveillance-eligible patients. He expands on how Decipher genomic classifier, PTEN loss, and activated CD4 activity at diagnosis are associated with adverse pathologic features among these patients. ...
Prostate Cancer
Advertisement
Latest News
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
The trial evaluated the data of treatment-naïve patients who underwent RP and received apalutamide as well as ADT.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Dr. Nyame shared highlights from his presentation on PC screening in high-risk groups as part of an AUA plenary session.
The utility of cADT in patients with prostate cancer with clinical relapse at PSMA PET is unknown.
Investigators found that the NCHT cohort demonstrated increased 3-year bPFS benefits compared to the NHT cohort.
Advertisement
Conference Coverage
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Advertisement
Advertisement
Latest News
Data on the type of treatment received in each line of therapy, as well as the attrition rates, were recorded.
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
